Enhanced nitric oxide release/synthesis in the posterior hypothalamus during nitroglycerin tolerance in rats

European Journal of Pharmacology

Volumn 472, Issue 3, 2003, Pages 179-187

  Ma, Sheng Xing ^a   Ji, Ang ^a   Pandjaitan, Marintan ^a   Ojije, Goodluck ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardiovascular action; Dialysis; Nitrate tolerance; Nitric oxide (NO); Nitroglycerin; Posterior hypothalamus

Indexed keywords

ARGININE DERIVATIVE; GLYCERYL TRINITRATE; N(G) PROPYLARGININE; NITRATE; NITRIC OXIDE; NITRITE; NITROPRUSSIDE SODIUM; PAPAVERINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; CHEMOLUMINESCENCE; CONTROLLED STUDY; DIALYSATE LEVEL; DOSE RESPONSE; DRUG RELEASE; DRUG RESPONSE; DRUG TOLERANCE; IMPLANTATION; LOW DRUG DOSE; MALE; MICRODIALYSIS; NONHUMAN; POSTERIOR HYPOTHALAMUS; PREMEDICATION; PRIORITY JOURNAL; PROVOCATION TEST; SYNTHESIS; TISSUE LEVEL;

EID: 0142059616     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01937-X     Document Type: Article

References (48)

1. Axelsson K.L., Ahlner J., Ljusegren M.E. Tolerance to organic nitroesters in experimental animals. An assessment of in vitro and in vivo investigations. Acta Pharm. Toxicol. 59(Suppl. VI):1986;121-128.
2. Bredt D.S., Snyder S.H. Nitric oxide - a novel neuronal messenger. Neuron. 8:1992;3-11.
3. Brien J.F., McLaughlin B.E., Breedon T.H., Bennett B.M., Nakatsu K., Marks G.S. Biotransformation of glyceryl trinitrate occurs concurrently with relaxation of rabbit aorta. J. Pharmacol. Exp. Ther. 237:1986;608-614.
4. Brien J.F., McLaughlin B.E., Kobus S.M., Kawamoto J.H., Nakatsu K., Marks G.S. Mechanism of glyceryl trinitrate-induced vasodilation. Relationship between drug biotransformation, tissue cyclic GMP elevation and relaxation of rabbit aorta. J. Pharmacol. Exp. Ther. 244:1987;322-327.
5. Boesgard S., Aldershvile J., Poulsen H.E., Loft S., Anderson M.E., Meister A. Nitrate tolerance in vivo is not associated with depletion of arterial or venous thiol levels. Circ. Res. 74:1994;115-120. Bousquet P., Schwartz J. Alpha-adrenergic drugs: pharmacological tools for the study of the central vasomotor control. Biochem. Pharmacol. 32:1983;1459-1965.
6. Bousquet P., Schwartz J. Alpha-adrenergic drugs: pharmacological tools for the study of the central vasomotor control. Biochem. Pharmacol. 32:1983;1459-1965.
7. Chen J., Zhang J., Stamler J.S. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc. Natl. Acad. Sci. 12:1999;8309-8311.
8. Dupuis J., Lalonde G., Lemieux R., Rouleau J.L. Tolerance to intravenous nitroglycerin in patients with congestive heart failure: role of increased intravascular volume, neurohormonal activation and lack of prevention with N-acetylcysteine. J. Am. Coll. Cardiol. 19:1990;923-931.
9. EL-Haddad M.A., Chao C.R., Ma S.X., Ross M.G. Neuronal nitric oxide modulates spontaneous and angiotensin II stimulated fetal swallowing behavior in the near term ovine fetus. Am. J. Physiol. 282:2002;R1521-R1527.
10. Erhardt L. Nitrate tolerance. State of the art-Chairman's summary. Acta Pharm. Toxicol. 59(Suppl. VI):1986;129-132.
11. Frazee J.G., Giannotta S.L., Stern W.E. Intravenous nitroglycerin for the treatment of chronic cerebral vasoconstriction in the primate. J. Neurosurg. 55:1981;865-868.
12. Garthwaite J., Charles S.L., Chess-Williams R. Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. Nature. 336:1988;385-388.
13. Ignarro L.J. Biosynthesis and metabolism of endothelium-derived nitric oxide. Annu. Rev. Pharmacol. Toxicol. 30:1990;535-560. Ignarro L.J., Lippton H., Edwards J.C., Baricos W.H., Hyman A.L., Kadowitz P.J., Gruetter C.A. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J. Pharmacol. Exp. Ther. 218:1981;739-749.
14. Ignarro L.J., Lippton H., Edwards J.C., Baricos W.H., Hyman A.L., Kadowitz P.J., Gruetter C.A. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J. Pharmacol. Exp. Ther. 218:1981;739-749.
15. Ignarro L.J., Fukuto J.M., Griscavage J.M., Rogers N.E., Byrns R.E. Oxidation of nitric oxide in aqueous solution to nitrite but not nitrate: comparison with enzymatically formed nitric oxide from L-arginine. Proc. Natl. Acad. Sci. 90:1993;8103-8107.
16. Imhof P.R., Rennwald D., Muller P., Howald H., Burkart F. Circulatory counter-regulations induced by continuous administration of nitroglycerin. Methods Find Exp. Clin. Pharmacol. 11:1989;409-414.
17. Katz R.J., Levy W.S., Buff L., Wasserman A.G. Prevention of nitrate tolerance with angiotensin converting enzyme inhibitors. Circulation. 83:1991;1271-1277.
18. Kaverina N.V. The mechanism of nitroglycerin action on the cardiac vessels. Bull. Eksp. Biol. Med. 49:1960;75-78.
19. Kaverina N.V., Vysotskaya N.B., Rosonov Yu.B., Shugina T.M. Connection between central action of glyceryl trinitrate and monoamine metabolism of the brain. Bull. Exp. Biol. Med. 64:1967;1310-1313. Kistler J.P., Lees R.S., Candia G. Intravenous nitroglycerin in experimental cerebral vasospasm: a preliminary report. Stroke. 10:1979;26-29.
20. Kistler J.P., Lees R.S., Candia G. Intravenous nitroglycerin in experimental cerebral vasospasm: a preliminary report. Stroke. 10:1979;26-29.
21. 2-formation. Biochem. J. 292:1993;545-550.
22. L'Heureux R., Dennis T., Curet O., Scatton B. Measurement of endogenous noradrenaline release in the rat cerebral cortex in vivo by transcortical dialysis: effects of drugs affecting noradrenergic transmission. J. Neurochem. 46:1986;1794-1801.
23. Ma S.X., Long J.P. Central noradrenergic activity is responsible for nitroglycerin-induced cardiovascular effects in the nucleus tractus solitarii. Brain Res. 559:1991;297-303. Ma S.X., Long J.P. Central noradrenergic activity and the cardiovascular effects of nitroglycerin and amyl nitrite. J. Cardiovasc. Pharmacol. 20:1992;826-836.
24. Ma S.X., Long J.P. Central noradrenergic activity and the cardiovascular effects of nitroglycerin and amyl nitrite. J. Cardiovasc. Pharmacol. 20:1992;826-836.
25. 3H]clonidine binding sites in cortex membranes. J. Pharmacol. Exp. Ther. 261:1992;1187-1194.
26. Ma S.X., Schmid P.G., Long J.P. Noradrenergic mechanisms and the cardiovascular actions of nitroglycerin. Life Sci. 55:1994;1595-1603.
27. Ma S.X., Abboud F.M., Felder R.B. Effects of L-arginine-derived nitric oxide synthesis on neuronal activity in nucleus tractus solitarius. Am. J. Physiol. 268 Regul. Integrative Comp. Physiol. 37:1995;R416-R487.
28. Ma S.X., Ignarro L.J., Byrns R., Li X.Y. Increased nitric oxide concentrations in posterior hypothalamus and central sympathetic function on nitrate tolerance following subcutaneous nitroglycerin. Nitric Oxide: Biol. Chem. 3:1999;153-161. Moncada S., Higgs E.A. Endogenous nitric oxide: physiology, pathology and clinical relevance. Eur. J. Clin. Investig. 21:1991;361-374.
29. Moncada S., Higgs E.A. Endogenous nitric oxide: physiology, pathology and clinical relevance. Eur. J. Clin. Investig. 21:1991;361-374.
30. Muiesan M.L., Boni E., Cefis M., Cerri B., Verdecchia P., Porcellati C., Agabiti-Rosei E. Efficacy of transdermal nitroglycerin in combination with an ACE-inhibitor in patients with chronic stable angina pectoris. J. Am. Coll. Cardiol. 2(Suppl A):1991;377A.
31. Nakata T., Berard W., Kogosov E., Alexander N. Microdialysis in the posterior hypothalamus: sodium chloride affects norepinephrine release, mean arterial pressure, heart rate and behavior in awake rats. Brain Res. Bull. 25:1990;593-598.
32. Napoli C., Ignarro L.J. Nitric oxide-releasing drugs. Annu. Rev. Pharmacol. Toxicol. 43:2003;97-123. Needleman P., Corr P.B., Johnson E.M. Drugs used for the treatment of angina: organic nitrates, calcium channel blockers, and β-adrenergic antagonists. Gilman A.G., Goodman L.S., Rall T.W., Murad F. The Pharmacological Basis of Therapeutics. 1985;806-826 Macmillan, New York.
33. Needleman P.J., Johnson E.M. Mechanism of tolerance development to organic nitrates. J. Pharmacol. Exp. Ther. 184:1973;709-715.
34. Needleman P., Corr P.B., Johnson E.M. Drugs used for the treatment of angina: organic nitrates, calcium channel blockers, and β-adrenergic antagonists. Gilman A.G., Goodman L.S., Rall T.W., Murad F. The Pharmacological Basis of Therapeutics. 1985;806-826 Macmillan, New York.
35. Panzica G.C., Garzino A., Ojeda E.G. Coexistence of NADPH-diaphorase and tyrosine hydroxylase in the mesencephalic catecholaminergic system of the Japanese quail. J. Chem. Neuroanat. 11:1996;37-47.
36. Parker J.O. Nitrate tolerance: a problem during continuous nitrate administration. Eur. J. Clin. Pharmacol. 38(Suppl. 1):1990;S21-S25.
37. Parker J.O., Parker J.D. Neurohormonal activation during nitrate therapy: a possible mechanism for tolerance. Am. J. Cardiol. 70:1992;93B-97B.
38. Rinde-Hoffman D., Glasser S.P., Arnett D.K. Update on nitrate therapy. J. Clin. Pharmacol. 31:1991;697-701.
39. Rush M.L., Lang W.J., Rand M.J. Studies on compensatory reflexes and tolerance to glyceryl trinitrate (GTN). Eur. J. Pharmacol. 16:1971;148-155.
40. Shonis C.A., Waldrop T.G. Augmented neuronal activity in the hypothalamus of spontaneously hypertensive rats. Brain Res. Bull. 30:1993;45-51. Silber S. Nitrates: Why and how should they be used? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate. Eur. J. Clin. Pharmacol. 38(Suppl. 1):1990;S35-S51.
41. Silber S. Nitrates: Why and how should they be used? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate. Eur. J. Clin. Pharmacol. 38(Suppl. 1):1990;S35-S51.
42. Simonian S.X., Herbison A.E. Localization of neuronal nitric oxide synthase-immunoreactivity within sub-populations of noradrenergic A1 and A2 neurons in the rat. Brain Res. 732:1996;247-252.
43. Tassorelli C., Joseph S.A. Nitroglycerin induces Fos immunoreactivity in brainstem and forebrain structures of the rat. Brain Res. 682:1995;167-181.
44. Tassorelli C., Joseph S.A. NADPH-diaphorase activity and Fos expression in brain nuclei following nitroglycerin administration. Brain Res. 695:1995;37-44.
45. Torfgard K., Ahnler J. Tissue levels of glyceryl trinitrate and cGMP after in vivo administration in rat, and the effect of tolerance development. Can. J. Physiol. Pharm. 69:1991;1257-1261.
46. Torfgard K., Ahnler J., Axelsson K.L., Norlander B., Bertler A. Tissue distribution of glyceryl trinitrate and the effect on cGMP levels in rat. Pharmacol. Toxicol. Ye S., Nosrati S., Campese V.M. Nitric oxide (NO) modulates the neurogenic control of blood pressure in rats with chronic renal failure (CRF). J. Clin. Invest. 99:1997;540-548. 64:1989;369-372.
47. Ye S., Nosrati S., Campese V.M. Nitric oxide (NO) modulates the neurogenic control of blood pressure in rats with chronic renal failure (CRF). J. Clin. Invest. 99:1997;540-548. Zhang H.Q., Fast W., Marletta M.A., Martasek P., Silverman R.B. Potent and selective inhibition of neuronal nitric oxide synthase by N-Propyl-L-arginine. J. Med. Chem. 40:1997;3869-3870.
48. Zhang H.Q., Fast W., Marletta M.A., Martasek P., Silverman R.B. Potent and selective inhibition of neuronal nitric oxide synthase by N-Propyl-L-arginine. J. Med. Chem. 40:1997;3869-3870.